Develops small molecule drugs for the treatment of cancer, targeting signaling pathways critical for tumor survival.
Curis, Inc. is a prominent biotechnology company based in Lexington, Massachusetts, specializing in the discovery and advancement of novel drug candidates aimed at treating various human cancers across the United States. At the forefront of its clinical stage portfolio is Emavusertib, an oral small molecule currently undergoing Phase 1/2 clinical trials for non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. The company's diverse pipeline also features CI-8993, a monoclonal antibody designed to counteract the V-domain Ig suppressor of T cell activation, demonstrating Curis's commitment to innovative therapies.
Further expanding its therapeutic offerings, Curis is developing Fimepinostat, an oral dual inhibitor targeting HDAC and PI3K enzymes, with potential applications in MYC-altered diffuse large B-cell lymphoma. Additionally, CA-170, another oral small molecule in its pipeline, holds promise for treating advanced solid tumors and lymphomas. The company is also advancing CA-327, an oncology drug candidate at the pre-investigational new drug stage, underscoring its dedication to pioneering cancer treatments.
Established in 2000, Curis has forged strategic collaborations with industry leaders such as F. Hoffmann-La Roche Ltd., Genentech Inc., and Aurigene Discovery Technologies Limited. These partnerships aim to accelerate the development and commercialization of groundbreaking therapies like Erivedge, an orally-administered hedgehog signaling pathway inhibitor for advanced basal cell carcinoma, and to explore new frontiers in immuno-oncology and precision oncology through the discovery of small molecule compounds. The company continues to drive innovation in cancer therapeutics, striving to improve outcomes for patients worldwide.